ReviewMediators of inflammation2025
Dual Roles of Prostaglandin E2 (PGE2) in Bone Remodeling and Pain Management: Bridging the Gap in Osteoarthritis Research.
Review in Mediators of inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- From depression to bone health: examining the skeletal effects of classical and rapid-acting antidepressants.The international journal of neuropsychopharmacology · 2026Review
- Skeletal interoception regulates joint homeostasis and PGE2-induced pain: implication of disease-modifying treatment.Bone research · 2026Review
- Formononetin attenuates glucocorticoid-induced osteoporosis via multiple osteoimmunological pathways: evidence from zebrafish and network pharmacology.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Nanoparticles isolated from the Gubi Zhitong formula alleviate knee osteoarthritis by reprogramming macrophages.Materials today. Bio · 2026Article
- Brain-bone Crosstalk after Neurotrauma: Dual Effects of Traumatic Brain Injury on Skeletal Remodeling.Current osteoporosis reports · 2026Review
- Tuina Attenuates Pain with Reduced Serum Pain- and Inflammation-Related Mediators and p38 MAPK Phosphorylation in Selected Brain Regions in Rats with Knee Osteoarthritis.Journal of pain research · 2026Article
- Inflammaging and osteoarthritis - therapeutic opportunities.Frontiers in immunology · 2026Review
- G protein-coupled receptor signaling in osteogenic bone mesenchymal stem/stromal cells.Frontiers in cell and developmental biology · 2026Review
- BeyondMedicina (Kaunas, Lithuania) · 2025Review
- Bone Marrow Edema and Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a bone disease mainly treated with nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve pain. However, the exact mechanisms underlying this disease remain elusive, which creates an attractive opportunity to explore the mechanisms and provide intentional treatments for OA. In this narrative review, we selected articles discussing advancements and applications of PGE2 to OA biology and pathology and discussed how PGE2 reacts during OA-associated pain, the resulting bone structural alterations, and the potential drugs or treatments for patients with OA. We aimed to summarize the accumulating evidence suggesting that prostaglandin E2 (PGE2) plays an important role in the central sensitization of OA-related pain, elucidating the precise mechanisms underlying the pain relief effects of NSAIDs. Additionally, we interpreted the potential mechanisms by which PGE2 influences bone repair and regeneration at different stages of bone remodeling in OA progression, which raises concerns regarding the side effects of NSAIDs in bone remodeling during disease progression. Finally, we discussed the potential therapeutic strategies for different stages of OA based on available evidence. This review focused on the newly found evidence for the novel functions of PGE2 in central sensitization and bone remodeling and provides possible future directions for the treatment of OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.